Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Promacta (eltrombopag) for the Treatment of Severe Aplastic Anaemia (SAA)

Drug Name (Brand / Generic)

Promacta / eltrombopag

Developed by

GlaxoSmithKline (GSK), Ligand Pharmaceuticals

Product Description

Thrombopoietin receptor antagonist

Current Indication

Severe Aplastic Anaemia (SAA)

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top